

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX becomes ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Singular Health Group Limited
ABN	58 639 242 765

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Denning Chong
Date of last notice	22 December 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	(1) Direct and (2), (3) and (4) Indirect
Nature of indirect interest (including registered holder)	(2) JCC HEALTH PTY LTD <THE JDE MEDVR A/C> - An entity controlled by Mr Chong, and of which he is a beneficiary (3) JDE CAPITAL PTY LTD <JDE CAPITAL A/C> - An entity controlled by Mr Chong, and of which he is a beneficiary (4) MAXWELL STANLEY CAPITAL PTY LTD <Maxwell Stanley Capital A/C> - an entity controlled by Mr Chong and of which he is a beneficiary
Date of change	22 June 2026

⁺ See [chapter 19](#) for defined terms.

No. of securities held prior to change	(1) 302,962 - ORDINARY FULLY PAID SHARES (2.1) 6,640,869 - ORDINARY FULLY PAID SHARES (2.2) 1,250,000 - UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027 (2.3) 5,000,000 - PERFORMANCE RIGHTS EXP 30/06/2028 (3.1) 8,667,706 - ORDINARY FULLY PAID SHARES (3.2) 1,818,182 - UNLISTED OPTIONS @ \$0.10 EXP 26/06/2026 (3.3) 10,000,000 - UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027 (3.4) 5,000,000 - PERFORMANCE RIGHTS EXP 30/06/2028 (4.1) 10,000,000 - UNLISTED OPTIONS @ \$0.25 EXP 15/04/2029 (4.2) 6,000,000 - UNLISTED OPTIONS @ \$0.55 EXP 30/11/2029
Class	(3.1) ORDINARY FULLY PAID SHARES (3.2) UNLISTED OPTIONS @ \$0.10 EXP 26/06/2026
Number acquired	(3.1) 1,818,182 - ORDINARY FULLY PAID SHARES
Number disposed	(3.2) (1,818,182 - UNLISTED OPTIONS @ \$0.10 EXP 26/06/2026)
Value/Consideration	\$181,818.20
No. of securities held after change	(2) 302,962 - ORDINARY FULLY PAID SHARES (2.1) 6,640,869 - ORDINARY FULLY PAID SHARES (2.2) 1,250,000 - UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027 (2.3) 5,000,000 - PERFORMANCE RIGHTS EXP 30/06/2028 (3.1) 10,485,888 - ORDINARY FULLY PAID SHARES (3.2) NIL - UNLISTED OPTIONS @ \$0.10 EXP 26/06/2026 (3.3) 10,000,000 - UNLISTED OPTIONS @ \$0.08 EXP 08/12/2027 (3.4) 5,000,000 - PERFORMANCE RIGHTS EXP 30/06/2028 (4.1) 10,000,000 - UNLISTED OPTIONS @ \$0.25 EXP 15/04/2029 (4.2) 6,000,000 - UNLISTED OPTIONS @ \$0.55 EXP 30/11/2029
Nature of change	Exercise of unlisted options

⁺ See [chapter 19](#) for defined terms.
01/01/2011 Appendix 3Y Page 2

Part 2 - Change of director's relevant interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Interest after change	N/A

Part 3 - ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺ closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See [chapter 19](#) for defined terms.